MX428795B - Derivados de furoindazol - Google Patents

Derivados de furoindazol

Info

Publication number
MX428795B
MX428795B MX2022007685A MX2022007685A MX428795B MX 428795 B MX428795 B MX 428795B MX 2022007685 A MX2022007685 A MX 2022007685A MX 2022007685 A MX2022007685 A MX 2022007685A MX 428795 B MX428795 B MX 428795B
Authority
MX
Mexico
Prior art keywords
diseases
compounds
inflammatory
disorders
metabolic
Prior art date
Application number
MX2022007685A
Other languages
English (en)
Other versions
MX2022007685A (es
Inventor
Antje Rottmann
Laak Antonius Ter
Frank Sacher
Gernot Langer
Hana Cernecka
Ondozabal Hideki Miyatake
Holger Siebeneicher
Katrin Nowak-Reppel
Nicole Schmidt
Olaf Panknin
Reinhard Nubbemeyer
Sabine Pilari
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2022007685A publication Critical patent/MX2022007685A/es
Publication of MX428795B publication Critical patent/MX428795B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención cubre compuestos de furoindazol de fórmula general (I): (ver Fórmula) (I) en la cual R1, R2, R3, R4, R5, R6, R7a y R7b son como se define en la presente, métodos para preparar dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos para elaborar composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en particular de enfermedades autoinmunes tales como esclerosis múltiple, psoriasis, artritis psoriásica, artritis reumatoidea, espondilitis anquilosante, lupus eritematoso sistémico, uveítis autoinmune primaria y secundaria, trastornos inflamatorios como endometriosis, enfermedades oculares inflamatorias, enfermedades renales inflamatorias, enfermedades hepáticas inflamatorias como enfermedades hepáticas no alcohólicas, alcohólicas y de hígado graso tóxicas, enfermedades pulmonares como asma, fibrosis pulmonar idiopática, enfermedad pulmonar obstructiva crónica, y trastornos metabólicos y metabólico-endocrinos como síndrome metabólico, resistencia a la insulina, diabetes mellitus tipo I y tipo II, y trastornos de síndrome de ovario poliquístico (PCOS), trastornos de dolor neuropático e inflamatorio en humanos y animales.
MX2022007685A 2019-12-19 2020-12-14 Derivados de furoindazol MX428795B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19217856 2019-12-19
PCT/EP2020/085905 WO2021122415A1 (en) 2019-12-19 2020-12-14 Furoindazole derivatives

Publications (2)

Publication Number Publication Date
MX2022007685A MX2022007685A (es) 2022-07-19
MX428795B true MX428795B (es) 2025-11-13

Family

ID=68965797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007685A MX428795B (es) 2019-12-19 2020-12-14 Derivados de furoindazol

Country Status (24)

Country Link
US (1) US12570666B2 (es)
EP (1) EP4077334B1 (es)
JP (1) JP7797389B2 (es)
KR (1) KR20220118480A (es)
CN (1) CN115135656B (es)
AR (1) AR120856A1 (es)
AU (1) AU2020408908A1 (es)
BR (1) BR112022011237A2 (es)
CA (1) CA3164963A1 (es)
CL (1) CL2022001644A1 (es)
CO (1) CO2022008338A2 (es)
CR (1) CR20220291A (es)
DO (1) DOP2022000126A (es)
EC (1) ECSP22047527A (es)
ES (1) ES3029866T3 (es)
GE (1) GEP20247585B (es)
IL (1) IL293968B2 (es)
JO (1) JOP20220156A1 (es)
MX (1) MX428795B (es)
PE (1) PE20221786A1 (es)
PH (1) PH12022551509A1 (es)
PL (1) PL4077334T3 (es)
TW (1) TW202136271A (es)
WO (1) WO2021122415A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2022179940A1 (en) * 2021-02-23 2022-09-01 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
CN115109072A (zh) * 2021-03-18 2022-09-27 武汉人福创新药物研发中心有限公司 一种gpr84拮抗剂及其制备方法和用途
WO2022229061A1 (en) * 2021-04-29 2022-11-03 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain
WO2024140969A1 (zh) * 2022-12-30 2024-07-04 广州市联瑞制药有限公司 三环类化合物及其制备方法和应用
WO2025247981A1 (en) 2024-05-31 2025-12-04 Bayer Aktiengesellschaft Furoindazole derivative pharmaceutical dosage

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT853083E (pt) 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
AU727654B2 (en) 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
WO2001083487A1 (en) * 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Froindazole derivative
US8357701B2 (en) * 2007-08-15 2013-01-22 University Of Miami Galactokinase inhibitors
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010078427A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
JP6293784B2 (ja) * 2012-12-20 2018-03-14 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための新規ジヒドロピリミジノイソキノリノン及びその医薬組成物（ｇｐｒ８４アンタゴニスト）
GB201411241D0 (en) * 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2016085990A1 (en) * 2014-11-24 2016-06-02 The Regents Of The University Of Michigan Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity
GB201506894D0 (en) 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP6918957B2 (ja) 2017-03-06 2021-08-11 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ Ｇｐｒ８４受容体拮抗剤およびその使用
EP3700527A4 (en) * 2017-10-25 2021-03-10 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHOD OF USING THEM
EP3556362A1 (en) 2018-04-16 2019-10-23 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors

Also Published As

Publication number Publication date
CO2022008338A2 (es) 2022-07-08
CR20220291A (es) 2022-08-10
WO2021122415A1 (en) 2021-06-24
IL293968B2 (en) 2026-02-01
US12570666B2 (en) 2026-03-10
BR112022011237A2 (pt) 2022-08-30
AU2020408908A1 (en) 2022-06-30
JP7797389B2 (ja) 2026-01-13
ECSP22047527A (es) 2022-07-29
GEP20247585B (en) 2024-01-25
CN115135656B (zh) 2024-06-14
DOP2022000126A (es) 2022-07-15
KR20220118480A (ko) 2022-08-25
ES3029866T3 (en) 2025-06-25
JP2023508908A (ja) 2023-03-06
WO2021122415A9 (en) 2022-06-30
JOP20220156A1 (ar) 2023-01-30
EP4077334C0 (en) 2025-03-12
MX2022007685A (es) 2022-07-19
CA3164963A1 (en) 2021-06-24
EP4077334A1 (en) 2022-10-26
PE20221786A1 (es) 2022-11-22
EP4077334B1 (en) 2025-03-12
TW202136271A (zh) 2021-10-01
US20230112499A1 (en) 2023-04-13
IL293968A (en) 2022-08-01
IL293968B1 (en) 2025-10-01
PH12022551509A1 (en) 2023-04-24
PL4077334T3 (pl) 2025-06-23
CN115135656A (zh) 2022-09-30
CL2022001644A1 (es) 2023-02-24
AR120856A1 (es) 2022-03-23